Ney Carter Borges: The APERITIF Trial Clarifies Rivaroxaban’s Role in LVT
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared on LinkedIn about a recent article by Etienne Puymirat et al in JAMA Cardiology:
”The APERITIF randomized clinical trial evaluated whether adding low-dose rivaroxaban (2.5 mg twice daily for 4 weeks) to dual antiplatelet therapy (DAPT) reduces left ventricular (LV) thrombus formation after anterior ST-segment elevation myocardial infarction (STEMI).
LV thrombus remains a clinically significant complication due to its association with systemic embolism, stroke, and mortality, particularly in large anterior infarctions.
Contemporary data suggest LV thrombus incidence may reach 15–25% in anterior MI when assessed with cardiac magnetic resonance (CMR), the gold-standard imaging modality .
In this multicenter PROBE-design trial conducted across 29 French centers, 560 patients (mean age 61.1 ± 11.6 years; 21.6% women) were randomized to DAPT plus rivaroxaban (n=277) or DAPT alone (n=283).
The primary endpoint was LV thrombus detected by contrast-enhanced CMR at 1 month. LV thrombus occurred in 13.7% of patients receiving rivaroxaban versus 16.6% with DAPT alone (absolute difference −2.9%; 95% CI −8.9% to 3.2%; P=0.34), indicating no statistically significant reduction .
Major adverse cardiovascular events were low and comparable (0.7% vs 1.1%).
Major bleeding (BARC ≥2) was infrequent and similar between groups (1.5% vs 0.7%), but minor bleeding (BARC 1) was significantly higher with rivaroxaban (16.4% vs 7.2%; difference 9.3%; 95% CI 3.6%–14.8%) .
In conclusion, low-dose rivaroxaban added to DAPT did not significantly reduce LV thrombus formation at 1 month but increased minor bleeding.
Given lower-than-expected event rates, the study may have been underpowered; thus, modest benefit cannot be excluded.”
Title: Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial
Authors: Etienne Puymirat, Gilles Soulat, Benoit Lattuca, Claire Bouleti, Nicolas Delarche, François Roubille, Yves Cottin, Didier Bression, Nicolas Combaret, Edouard Gerbaud, Thibaut Lhermusier, Loic Biere, Olivier Dubreuil, Elie Mousseaux, Philippe Gabriel Steg, Guillaume Cayla, Gilles Lemesle, Johanne Silvain, Jean-Guillaume Dillinger, Jean-Louis Georges, Grégory Ducrocq, Thibaud Genet, Jean-François Morelle, Gilles Montalescot, Laurence Berard, Alexandra Rousseau, Maxime Soen, Tabassome Simon, Nicolas Danchin for the APERITIF study investigators
Read the Full Article on JAMA Cardiology
Stay updated on all scientific advances with Hemostasis Today.
-
Feb 26, 2026, 14:44Wolfgang Miesbach: Synovitis and Haemophilia in Focus at GTH2026
-
Feb 26, 2026, 14:40Al-Ola Abdallah: How Much Does It Cost to Publish in Hematology and Oncology Journals
-
Feb 26, 2026, 14:38Chris Hillis: Newly Updated Choosing Wisely Canada – Hematology Recommendations
-
Feb 26, 2026, 14:37Inflammatory-Coagulation Cascade Interactions in Trauma-Induced Coagulopathy – JTH
-
Feb 26, 2026, 14:36Tareq Abadl: Protective Role of Sickle Cell Trait in Malaria
-
Feb 26, 2026, 14:33Nita Radhakrishnan: Strengthening Comprehensive Thalassemia Care at UP HEMATOCON
-
Feb 26, 2026, 12:05Anirban Sen Gupta: PlateChek Links Platelet Status to Hemostasis Outcomes in Whole Blood
-
Feb 26, 2026, 08:11Florine Fisette: Strengthening Blood Banking and Life-Saving First Aid Training Across Burundi
-
Feb 25, 2026, 16:47Alan Nurden: Platelet Defects Explain Bleeding in EHDS Patients